Regeneron Pharmaceuticals, Inc.
Treatment Of Hyperglycemia With Solute Carrier Family 39 Member 5 (SLC39A5) Inhibitors

Abstract:

The present disclosure provides methods of treating subjects having increased serum glucose level and/or hyperglycemia, methods of identifying subjects having an increased risk of developing increased serum glucose level and/or hyperglycemia, and methods of detecting human Solute Carrier Family 39 Member 5 variant nucleic acid molecules and variant polypeptides.